Release Date: April 02, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- AngioDynamics Inc (ANGO, Financial) reported a strong third quarter with total worldwide revenue of $72 million, representing a growth of over 9% year over year.
- The MedTech segment experienced significant growth, increasing by 22%, driven by strong performance across all platforms.
- The Auryon platform continued its robust performance, growing approximately 17% over the prior year, marking 15 consecutive quarters of double-digit growth.
- Mechanical thrombectomy products, AlphaVac and AngioVac, showed impressive growth, with combined revenue increasing by approximately 47% year over year.
- The NanoKnife segment saw a 16% growth in probe revenue, supported by an expanded FDA indication for prostate tissue ablation, enhancing its market potential.
Negative Points
- Despite improvements, AngioDynamics Inc (ANGO) reported an adjusted EPS loss of $0.08 per share, although this was an improvement from a loss of $0.16 per share in the previous year.
- The Med Device segment showed minimal growth, with revenue increasing by only 1% over the previous year.
- Capital sales for NanoKnife were lower than expected, declining 21.6% during the quarter.
- The company is still navigating complex reimbursement processes for the NanoKnife system, with significant reliance on future CPT code implementation.
- AngioDynamics Inc (ANGO) utilized $13.2 million in operating cash during the quarter, impacting its cash flow, although it expects to generate cash in the fourth quarter.
Q & A Highlights
Q: Do you think the $6.8 million revenue from AngioVac is a good new base for the business going forward?
A: Yes, we believe that the $6.8 million is a solid base for AngioVac. We are pleased with the synergistic portfolio of AngioVac and AlphaVac P/E, which is driving increased awareness and performance. We expect AngioVac to continue growing, although not at the same rapid rate, and anticipate further growth from AlphaVac as adoption increases. - Unidentified Company Representative
Q: Can you provide details on the percentage of revenue attributed to prostate treatments and the impact of the CPT level one code?
A: Prostate treatments now account for more than half of our NanoKnife procedures, surpassing liver and pancreas treatments. We are seeing increasing interest and adoption following FDA approval. Regarding reimbursement, we expect the first readout in July, with the CPT1 code becoming permanent in January. We are actively working to ensure coverage from private payers. - James Clemmer, President, CEO
Q: Given the strength in AngioVac post-AlphaVac launch, are there plans to expand the commercial team for mechanical thrombectomy?
A: Our team is well-positioned in key markets, and we are seeing success with both AngioVac and AlphaVac. We plan to expand the sales force over the course of the year, similar to how we built out Auryon, to support further growth and adoption. - James Clemmer, President, CEO
Q: How is the EU launch of Auryon progressing, and what are the expectations for this market?
A: We have conducted extensive training and education globally, and expect to see revenue contributions from Auryon in Q4. While the international market is smaller than the US, we anticipate sequential growth and are pleased with the traction we are gaining. - James Clemmer, President, CEO
Q: Can you provide an update on the Ambition BTK study and its potential impact on the market?
A: We expect to begin enrollment in the next quarter. The study aims to demonstrate that Auryon, used below the knee with balloon angioplasty, provides better results than angioplasty alone. This could support Auryon's use and potentially expand the atherectomy market. - Unidentified Company Representative
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
